

**Diabetes-related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept versus Other Targeted DMARDs**

Vardhaman Patel • Zulkarnain Pulungan • Anne Shah • Barton Jones • Allison Petrilla • Leticia Ferri • Xue Han • Kaleb Michaud

V. Patel (corresponding author) • L. Ferri • X.Han

Bristol Myers Squibb, Lawrence Township, NJ, USA

e-mail: [vardhaman.patel@bms.com](mailto:vardhaman.patel@bms.com)

Z. Pulungan\* • A.Shah\* • B. Jones\* • A. Petrilla\*

Avalere Health, Washington, DC, USA


\*At the time the study was conducted

K. Michaud

University of Nebraska Medical Center, Omaha, NE, & Forward, The National Databank for Rheumatic Diseases, Wichita, KS, USA

## SUPPLEMENTARY MATERIAL

**Fig. S1 Patient Attrition Steps for TNFi-experienced and tDMARD Naïve Patient Cohorts**



<sup>a</sup>TNFi drug included adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab;  
<sup>b</sup>Other Non-TNFi drug included anakinra, sarilumab, tocilizumab, baricitinib, rituximab, and tofacitinib; <sup>c</sup>Patient counts are mutually exclusive and reflects those beneficiaries who met all the inclusion/exclusion criteria and had earliest qualifying index event. A hierarchical order was applied to increase the sample size. Patients were assigned to abatacept first followed by a non-TNFi and then to TNFi. Among TNFi, patients were assigned in the following order: (1) adalimumab, (2) certolizumab pegol, (3) etanercept, (4) golimumab, and (5) infliximab. Patients were followed from index date and ended at the earliest of the end of study period, patient disenrollment, death, switch to another tDMARD, or discontinuation of the index drug. *HCPC* Healthcare Common Procedure Coding System, *NDC* National Drug Code, *RA* rheumatoid arthritis, *T2DM* type 2 diabetes mellitus, *tDMARD* targeted disease-modifying antirheumatic drug, *TNFi* tumor necrosis factor- $\alpha$  inhibitor.

**Table S1** Sensitivity Analysis Outcomes with Additional 90 days for End of Index treatment Date

Variable	TNFi-experienced Patient Cohort				tDMARD Naïve Patient Cohort			
	N	Mean	SD	Median	N	Mean	SD	Median
T2DM-related Medical Costs PPPM								
Post-Index Medicare DCSI Medical Payment Amount								
Abatacept	2,169	\$652	\$1,753	\$97	2,667	\$807	\$2,154	\$131
TNFi	2,169	\$777	\$2,155	\$114	2,667	\$795	\$2,086	\$119
Post-Index Medicare DCSI Medical Payment Amount								
Abatacept	2,118	\$676	\$1,840	\$96	2,247	\$810	\$2,179	\$123
Non-TNFi	2,118	\$785	\$2,264	\$119	2,247	\$1,012	\$2,585	\$108
Rate of Inpatient Stay P1000PPM								
Post-Index DCSI IP Stay								
Abatacept	2,169	27	70	0	2,667	31	77	0
TNFi	2,169	30	76	0	2,667	32	76	0
Post-Index DCSI IP Stay								
Abatacept	2,118	28	75	0	2,247	31	78	0
Non-TNFi	2,118	32	77	0	2,247	41	97	0

Length of follow-up = index drug + days' supply + 90 days. *DCSI*, diabetes complications severity index, *IP* inpatient, *P1000PPM* per 1000 patients per month, *PPPM* per-patient-per-month, *SD* standard deviation, *T2DM* type 2 diabetes mellitus, *tDMARD* targeted disease-modifying antirheumatic drug, *TNFi* tumor necrosis factor- $\alpha$  inhibitor.